auy922: all 23 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFRCompletedNCT01854034Phase 2Results posted
• AUY922 for Advanced ALK-positive NSCLCCompletedNCT01752400Phase 2Results posted
• HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ETTerminatedNCT01668173Phase 2Results posted
• An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR MutationsTerminatedNCT01646125Phase 2Results posted
• A Study of the HSP90 Inhibitor AUY922TerminatedNCT01485536Phase 2Results posted
• Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal TumorCompletedNCT01404650Phase 2Results posted
• Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung CancerCompletedNCT01259089Phase 1/2Results posted
• A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid TumorsCompletedNCT01226732Phase 1Results posted
• A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.CompletedNCT01124864Phase 2Results posted
• AUY922 in Patient With Stage IV NSCLCCompletedNCT01922583Phase 2
• Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung CancerCompletedNCT01784640Phase 1
• Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung CancerCompletedNCT01772797Phase 1
• PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric CancerCompletedNCT01613950Phase 1
• Hsp90 Inhibitor AUY922 in Treating Older Patients With Advanced Solid MalignanciesTerminatedNCT01602627Phase 1
• Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line ChemotherapyTerminatedNCT01484860Phase 2
• Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive PatientsTerminatedNCT01402401Phase 2
• A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) PatientsStatus unknownNCT01389583Phase 2
• AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast CancerWithdrawnNCT01361945Phase 1/2
• Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal CancerCompletedNCT01294826Phase 1
• Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With TrastuzumabCompletedNCT01271920Phase 1/2
• Dose Escalation Study of AUY922 in Advanced Solid Malignancies in JapanCompletedNCT01132625Phase 1
• Phase II Trial of AUY922 vs. Comparators in Advanced Gastric CancerCompletedNCT01084330Phase 2
• Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer PatientsCompletedNCT00526045Phase 1/2

← auy922 overview